The Value of New Pharmaceuticals
In the final report for the programme, Professor Bengt Jönsson and Katarina Steen Carlsson, PhD, summed up the most important conclusions from the programme.
They noted that new, innovative medicines can provide health benefits to patients as well as socioeconomic benefits through shorter waiting times and lower rates of absence from work due to illness. But today’s system for pricing and evaluating new medicines has shortcomings that impede the effective use of medicines in health care. New medicines have become more expensive to develop and more difficult to use. A faster, more orderly introduction of new medicines is important both for more effective medicine use in health care and to establish better conditions for clinical pharmaceutical research in Sweden.
New medicines must have a better chance
- The authors present several proposals to establish better conditions for developing, introducing and evaluating new medicines in Swedish health care:
- Abolish price controls. Abolish state price controls and apply a payment system that takes into account the different values a medicine has depending on what illness is treated.
- A state budget for new medicines. Finance new, innovative medicines with a state budget and monitor the effects with systematic analysis.
- National coordination. Coordinate resources for evaluation and introduction of innovative medicines at the national level.